Design of a Tumor-Homing Cell-Penetrating Peptide

Chemotherapy is often limited by toxicity to normal cells. Therefore, an ideal anticancer drug should discriminate between normal tissue and tumors. This would require a target receptor molecule mostly present in tumors. The cyclic peptide cCPGPEGAGC (PEGA) is a homing peptide that has previously been shown to accumulate in breast tumor tissue in mice. PEGA peptide does not cross the plasma membrane per se; however, when attached to the cell-penetrating peptide pVEC, the conjugate is taken up by different breast cancer cells in vitro. Additionally, the homing capacity of the PEGA-pVEC is conserved in vivo, where the conjugate mainly accumulates in blood vessels in breast tumor tissue and, consequently is taken up. Furthermore, we show that the efficacy of the anticancer drug, chlorambucil, is increased more than 4 times when the drug is conjugated to the PEGA-pVEC chimeric peptide. These data demonstrate that combining a homing sequence with a cell-penetrating sequence yields a peptide that combines the d...

[1]  E. Ruoslahti,et al.  Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Zellmer,et al.  Aminopeptidase P – a Cell-Surface Antigen of Endothelial and Lymphoid Cells: Catalytic and Immuno-Histotopical Evidences , 1998, Biological chemistry.

[3]  T. Bártfai,et al.  Design of chimeric peptide ligands to galanin receptors and substance P receptors. , 2009, International journal of peptide and protein research.

[4]  R. Fischer,et al.  Endocytosis and cationic cell-penetrating peptides--a merger of concepts and methods. , 2005, Current pharmaceutical design.

[5]  Erkki Ruoslahti,et al.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.

[6]  W. Mattes,et al.  DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. , 1986, Nucleic acids research.

[7]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[8]  Eric Vives,et al.  Cell-penetrating Peptides , 2003, The Journal of Biological Chemistry.

[9]  R. Brasseur,et al.  Deletion analogues of transportan. , 2000, Biochimica et biophysica acta.

[10]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[11]  D. Hanahan,et al.  Lymphatic zip codes in premalignant lesions and tumors. , 2006, Cancer research.

[12]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[13]  R. Brasseur,et al.  New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Ű. Langel,et al.  Cell-penetrating peptides--a brief introduction. , 2006, Biochimica et Biophysica Acta.

[15]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[16]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[17]  T. Bártfai,et al.  VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. , 2001, Experimental cell research.

[18]  W. Lehmann,et al.  Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. , 2000, Journal of medicinal chemistry.

[19]  E. Ruoslahti,et al.  Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Faguet,et al.  Chronic lymphocytic leukemia: an updated review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Pooga,et al.  Prediction of Cell-Penetrating Peptides , 2005, International Journal of Peptide Research and Therapeutics.

[22]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[23]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[24]  E. Ruoslahti.  Drug targeting to specific vascular sites. , 2002, Drug discovery today.

[25]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Nordén,et al.  Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. , 2003, Biochemical and biophysical research communications.

[27]  Jing Zhang,et al.  Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications , 1991 .

[28]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.